Epic Sciences can identify gene amplifications, deletions and rearrangements by DNA fluorescence in situ hybridization (FISH). This test consists of:
The data below shows CTCs that were evaluated using a PTEN FISH assay developed on the Epic platform. PTEN status in CTCs was compared to matched, archived and fresh tumor tissue samples from 41 mCRPC patients. We found that PTEN status in CTCs and fresh tissue were concordant. There was more discordance when comparing CTCs to archived primary tissue. Analysis of gene status in CTCs may be representative of the current disease and could serve as a non-invasive solution for genetic characterization.
Representative images of PTEN and CEP10 genotype in patient CTCs. Top panel shows CTCs that were identified by immunofluorescence and bottom panel shows the PTEN FISH analysis of the same CTCs indentified above.
Epic Sciences has developed numerous assays, which are being used to test more than 10,000 patient blood samples from clinical trial sites located in North America, Europe and Asia. These protein, FISH and genomic assays are designed to measure protein abnormalities in CTCs for 12 different cancer types.
All of Epic Sciences’ offerings can be included in your companion diagnostic assay to ensure the right treatment for the right patient at the right time. Request more information on CDx capabilities here: email@example.com